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Background: Stereotactic Ablative RadioTherapy (SABR) of lung tumors/metastases has been shown to be an
effective treatment modality with low toxicity. Outcome and toxicity were retrospectively evaluated in a unique
single-institution cohort treated with intensity-modulated image-guided breath-hold SABR (igSABR) without external
immobilization. The dose–response relationship is analyzed based on Biologically Equivalent Dose (BED).
Patients and methods: 50 lesions in 43 patients with primary NSCLC (n = 27) or lung-metastases of various primaries
(n = 16) were consecutively treated with igSABR with Active-Breathing-Coordinator (ABC®) and repeat-breath-hold
cone-beam-CT. After an initial dose-finding/-escalation period, 5x12 Gy for peripheral lesions and single doses of 5 Gy to
varying dose levels for central lesions were applied. Overall-survival (OS), progression-free-survival (PFS), progression
pattern, local control (LC) and toxicity were analyzed.
Results: The median BED2 was 83 Gy. 12 lesions were treated with a BED2 of <80 Gy, and 38 lesions with a BED2
of >80 Gy. Median follow-up was 15 months. Actuarial 1- and 2-year OS were 67% and 43%; respectively. Cause
of death was non-disease-related in 27%. Actuarial 1- and 2-year PFS was 42% and 28%. Progression site was
predominantly distant. Actuarial 1- and 2 year LC was 90% and 85%. LC showed a trend for a correlation to BED2
(p = 0.1167). Pneumonitis requiring conservative treatment occurred in 23%.
Conclusion: Intensity-modulated breath-hold igSABR results in high LC-rates and low toxicity in this unfavorable patient
cohort with inoperable lung tumors or metastases. A BED2 of <80 Gy was associated with reduced local control.
Keywords: Hypofractionated intensity modulated breath-hold image-guided (ig)SABR, Lung tumors, Lung metastases,
Local control, Survival, ToxicityIntroduction
Standard therapy for stage I-II lung cancer or solitary
lung metastases is surgical resection. SABR (Stereotactic
Ablative Radiotherapy) is a non-invasive, effective and low-
toxicity alternative for medically inoperable patients [1].
SABR of lung lesions poses a special challenge for several
reasons such as the highly volume-dependent radiosensi-
tivity of healthy lung tissue and surrounding organs at risk
(OAR, e.g. oesophagus, heart), breathing-induced motion* Correspondence: judit.boda-heggemann@umm.de
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distribution, and reproduction in any mediumof pulmonary targets and the dosimetrically difficult
situation of a high-density tumor lesion surrounded by
low-density lung tissue. The lung itself is one of the most
radiation-sensitive organs with two different manifestations
of radiation damage with different time frames. As a severe
early (subacute) side effect of radiation therapy, pneumon-
itis occurs in 5-15% 4–6 weeks after conventionally
fractionated large-volume thoracic irradiation. The inci-
dence of radiation pneumonitis depends on the radiation
dose and the irradiated volume of the normal lung tissue
[2]. As a late side effect and consequence of radiation
pneumonitis, pulmonary fibrosis may arise, rendering
the affected tissue without function.ed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patients (n = 43) characteristics
Characteristics Total (Percentage)
Gender:
Male 32 (74%)
Female 11 (26%)
Age:
Ys, Median; (range) 69 (49–84)
Tumor entities:
NSCLC 27 (63%)
Lung metastasis of various primary tumors 16 (37%)
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is the most important part of improvement of local control
of lung targets and therefore should be aimed at [3] since
both model calculations [4] and clinical data suggest that
doses necessary for tumor ablation are higher than initially
thought [5]. To reliably and accurately create the required
highly conformal radiation doses necessary for lung target
irradiation, improvement of imaging, planning, dose cal-
culation and delivery tools is needed.
The development of devices that enable image guided
radiotherapy (IGRT) together with non-invasive lung
immobilization makes a “frameless” stereotactic approach
possible [6]. Breath-hold techniques for tumor immobilisa-
tion facilitate the delivery of high doses to the PTV while
maximally sparing OAR [7]. Dosimetric comparisons
between free-breathing and breath hold radiotherapy for
lung cancer [8] have shown an improved target conformity
index and less dose to the heart and healthy lung if
compared to free breathing planning. Computer-controlled
breath-hold with the ABC®-system (Active Breathing
Coordinator, Elekta AB, Stockholm, Sweden) in combin-
ation with daily image-guidance has been successfully
implemented for targets that move with spontaneous
breathing [9].
Recent pooled analyses of almost 500 patients with stage
I NSCLC have shown excellent results with local control
rates of 92% and low toxicity [10]. Other large multicenter
trials, for example the RTOG 1021 trial, comparing the
sublobular resection with SABR in patient cohorts, with
high risk of complications with more extensive surgery are
currently in progress.
In this retrospective evaluation, we assess outcome and
toxicity in a unique single-institution series of patients
who received volume-image-guided, intensity modulated
breath-hold lung SABR with both primary lung and
metastatic lesions, undergoing no external immobilization.
Patients and methods
Patients
Between 2002 and 2009 50 lesions of 43 consecutive
patients with NSCLC (n = 27, St. I-II in the primary
situation and III-IV including patients with controlled
brain metastases or local relapse after primary stand-
ard therapy) and lung metastases of various primary
tumors (n = 16; 2 melanoma; 3 oropharyngeal, 1 laryn-
geal, 1 prostate, 4 colorectal, 1 pancreatic and 1 breast
cancer; 1 transitional cell and 2 renal cell carcinoma)
were consecutively treated with intensity-modulated
breath-hold igSABR after informed consent. All lesions
were considered to be technically or medically inoper-
able by an interdisciplinary tumor-conference. Patient
and tumor characteristics are summarised in Table 1,
while the NSCLC series is further described in detail in
Table 2.Data were evaluated retrospectively regarding overall
survival (OS), progression-free-survival (PFS), progression
pattern, local control (LC), acute and late toxicity based
on clinical symptoms and CTC/LENT-SOMA scales.
Radiotherapy planning, dose calculation and treatment
Planning CT scans were acquired with a spiral-CT
(Somatom Emotion, Siemens, Erlangen, Germany, there-
after Brilliance Big Bore Oncology, Philips, Hamburg,
Germany) after an initial patient training session in
inspiratory breath-hold at approximately 70% of vital
capacity with ABC® [9]. Radiotherapy planning was initially
performed as manually weighted Intensity Modulated
RadioTherapy (IMRT) with OTP (Theranostic GmbH,
Solingen, Germany) and thereafter with inverse planned
step-and-shoot IMRT or VMAT (Volumetric Modu-
lated Radiotherapy) with Monaco® (Elekta AB, Stockholm,
Sweden).
PTV was calculated from CTV by adding a 5 mm
margin radially and 10 mm in the craniocaudal direction
to compensate residual intrafractional error of the ABC®-
based positioning [11].
Dose calculation was performed initially by a pencil
beam (PB) algorithm (11 patients), thereafter both with
PB and collapsed cone (CC) algorithms (32 patients).
After the change to CC algorithm, the PB was still cal-
culated in order to compare the resulting nominal dose
distributions.
Dose prescription was initially performed to the isocen-
ter (forward-planned IMRT), typically in the vicinity of
the median dose) and later as the median dose in the PTV
(inverse IMRT) with the 90% isodose line covering the
PTV. Dose constraints for OAR were as shown in Table 3
[5,12-15]. The planning constraints are the constraints
for the final dose level of typically 5x12 Gy. While we
attempted to fulfill the planning goals whenever possible
for this regimen, we had, however, for example for tumors
close to the chest wall or the plexus, to deviate from these
constraints on occasion depending on individual phys-
ician and patient preference if adhering to constraints
Table 3 Dose constraints for OAR (OAR, Organs at risk;
Dmax, maximal dose in PTV; V15 and V20, percentage of
irradiated tissue covering the 15 or 20 Gy isodose
[5,11-14])
OAR Dose constraint
Healthy lung V15 <30%
Healthy lung V20 <20%
Spinal cord Dmax 18-20 Gy
Trachea/main bronchus Dmax 36 Gy
Esophagus Dmax 18 Gy
Brachial plexus Dmax 18 Gy
Ribs/Thoracic wall Dmax 30 Gy
Heart and major vessels Dmax 30 Gy
Skin Dmax 40 Gy
Table 2 Further characteristics of patients with NSCLC
(n = 27)
Characteristics Staging
Histologic diagnosis
Squamous cell carcinoma
Adenocarcinoma others
9 (33%) 13 (48%)
5 (19%)
Stage(AJCC)
Ia 6 (22%)
Ib 4 (15%)
IIa 3 (11%)
IIb 3 (11%)
IIIa* 5 (19%)
IIIb* 1 (3%)
IV* 5 (19%)
Chemotherapy before or
after RT
Tumor:
T1a 2 (7%)
yes 12 (45%) T1b 10 (37%)
T2a 5 (19%)
no 15 (55%) T2b 1 (3%)
T3 4 (15%)
T4 5 (19%)
Comorbidity: Lymphnodes
N0 18 (67%)
N1 5 (19%)Pulmonary disease (COPD) 6 (22%)
Cardiovascular disease 7 (26%)
Both 12 (45%) N2 3 (11%)
None of the above 2 (7%) N3 1 (3%)
Metastasis:
M0 22 (82%)
M1a 1 (3%)
M1b 4 (15%)
Detailed characteristics of patients with NSCLC (n = 27).
*Patients treated with SBRT in relapse situation or with stable brain metastases
based on patient wish and individual therapy decision.
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Dose constraints for the other regimens were adjusted
for each regimen.
PTV-coverage was analysed based on relevant parameters
(D99 (dose encompassing 99% of the PTV), minimal,
maximal, mean and median PTV-dose.
Implementing results from published literature reports
[5,13-16] regarding dose escalation and fractionation, dose
to the patients was adjusted during the reported period
and varied between single-fraction doses of 20-26 Gy
initially (depending on tumor and healthy lung volume)
and various hypofractionated regimens with the current,
final protocol prescribing 5x12Gy every other day to per-
ipheral tumors and 12x5Gy to central lesions [15]. For
exact fractionation schedules of each lesion, see Additional
file 1: Table S1.To be able to retrospectively compare these various
fractionation regimens, we introduced Biologically Effective
Dose in 2 Gy fractions (BED2 [17]). BED2 was calculated
[18] with an assumed α/β ratio of 10 with the following
formula: BED2 =Dx(d + α/β)/(2 + α/β).
Patients were treated as described previously [17].
Shortly, a linac with 6MV photons was used (Synergy®,
Elekta AB, Stockholm, Sweden). Daily image-guidance
was performed with EPIDs (Electronic Portal Imaging
Device) and since 2005 with repeat breath-hold CBCT
(XVI®, Elekta AB, Stockholm, Sweden [17,19]). Planning-
CT images were matched online with the daily CBCT
images using manual fusion with respect to soft-tissue
anatomy [20]. Online surveillance of breath-hold was
performed based on the continuous acquisition of MV-
frames during irradiation allowing position verification of
the tumor itself, if possible, or of a surrogate structure
such as the diaphragm [6].
Patient follow-up (FU) was scheduled 6 weeks after
radiotherapy and every 3 months thereafter with clinical
examination and thoracic CT with i.v. contrast. An assess-
ment of tumor response was performed using the RECIST
(Response Evaluation and Criteria in Solid Tumors) criteria.
Response was graded as complete response (CR), partial
response (PR), stable disease (SD) or progression.
Acute (first 90days) and late toxicity (>90 days) was
evaluated based on clinical symptoms (graded based on the
CTC-scale in the acute phase and on the LENT-SOMA
criteria (late effects in normal tissues subjective, objective,
management and analytic scales) in the late phase). Re-
corded clinical symptoms were general condition, cough-
ing, dyspnoea, pneumonitis, pulmonary oedema, dysphagia,
pleural effusion, fever and skin symptoms for assessing
acute toxicity; rib fracture, pulmonary fibrosis, thoracic
pain, dyspnoea and coughing for late toxicity. Pneumonitis
analysis was based on presence of symptoms requiring
treatment and thoracic CT imaging.
Figure 1 Kaplan-Meier-plots for overall survival, progression free survival and local control. A: Overall Survival of all patients, B: Progression
Free Survival of all patients, C: Local Control of all lesions, D: Local Control for lesions treated with a BED2 > 80 Gy (red) and a BED2 < 80 Gy (black). The
p-value shows a trend for a better local control with higher BED2. N: Number of lesions at risk at every given time-point.
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Statistical analysis was performed with the SAS-software,
release 9.01 (SAS, Cary, NC, USA). OS (Overall-Survival),
PFS (Progression-Free-Survival) and LC (Local Control)
were recorded and subject to actuarial analysis. OS was
calculated from the day of irradiation until either the day
of death (event) or the day of the last FU (censored data).
PFS was calculated from the day of irradiation until either
the day of relapse or death (events) or the last FU without
relapse (censored data when at the last FU the patient
lived without any evidence of progression). LC was calcu-
lated from the day of irradiation until either the day of local
progression (event) or the last FU/death without local pro-
gression (censored data). For LC, number of patients at risk
was calculated for each time point. Kaplan-Meier-plots for
OS, PFS and LC were calculated in order to assess median
survival/control times. Correlation of the local control time
with PTV size and BED2 was analysed by the Kaplan-MeierFigure 2 Radiotherapy plan (A), pre-radiotherapy CT (B), follow-up CT
Complete regression of the irradiated lesion can be observed without marklog-rank test. P-values < 0.05 were considered as significant,
0.05 < p < 0.15 as a trend to significance.
Results
Radiotherapy data
All patients managed to achieve sufficient repeat breath-
hold with ABC®.
Mean BED2 (Biologically Effective Dose) was 87±20 Gy
(median 83 Gy). 12 lesions were treated with a BED2
of <80 Gy, and 38 lesions with a BED2 of >80 Gy (range
50-150Gy). PTV-volume was 94±90 cm3 (median 69 cm3).Follow-up (FU), Overall-Survival (OS),
Progression-free-survival (PFS) and Local Control (LC)
Median follow-up (FU) was 15 months for all patients.
Median FU was 24 months for living patients. 12 patients
are alive, 31 patients have died.s 2 months post-RT (C) and 1 year post-RT (D) of a typical patient.
ed changes in healthy lung structure.
Table 4 Dyspnea and coughing as side effect in the acute
and chronic phase after SABR, classified by CTC
CTC
grade
Dyspnea Coughing
Pre-
treatment
Acute
phase
Chronic
phase
Pre-
treatment
Acute
phase
Chronic
phase
Grade 1 2 3 4 4 12 6
Grade 2 11 16 14 0 2 0
Grade 3 3 2 1 0 0 0
Grade 4 3 7 3 0 0 0
Patients, n = 43.
Table 5 Acute toxicity, reported separately for NSCLC
(n = 27) and metastases (n = 16); dyspnea and coughing
as grade difference between pre-therapeutic state and
acute phase
CTC
grade
Δdyspnea Δcoughing Pneumonitis
NSCLC met NSCLC Met NSCLC met
Grade 1 2 3 2 3 5 2
Grade 2 2 2 1 0 2 4
Grade 3 0 0 0 0 1 2
grade 4 0 0 0 0 0 0
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without significant difference between patients with primary
lung tumors or metastases (p = 0.3689). Actuarial 1-year
OS was 67% (95% CI: 53% - 82%) and 2-year OS was 43%
(95% CI: 27% - 59%) (Figure 1A). 28% of the patients died
for non-disease related reasons (cardiovascular events or
infections). Cause of death was systemic metastases out-
side the lung in 30% and progression of the primary tumor
in 12% (1 oropharyngeal cancer, 4 primary lung tumor).
Cause of death in one patient could not be determined
with certainty although the date of death was confirmed
by authorities. Actuarial 1-year PFS was 43% (95% CI:
27%-59%) and 2-year PFS was 29% (95% CI: 13%-44%;
Figure 1B). Site of progression was predominantly distant
(60% distant metastases (11 lung, 8 liver, 7 bone, 3 brain, 3
distant lymph node, 2 soft tissue, 2 spleen, 2 pleural, 1
peritoneal carcinomatosis, 1 adrenal gland, 1 kidney, 1
breast) and 32% mediastinal lymph nodes).
In 36 patients, size-reduction of the irradiated lesion
was observed. In 5 patients, lesions remained unchanged;
the lesion in one patient was progressive. Median time to
response was 1.6 months (2.7 ± 2.6months (MV± SD),
typically at first reported FU). Complete response of the
irradiated lesion was observed in 45 cases. Later local
progression after initial regression was observed in 5
lesions after a median of 7 months. A typical patient
example is shown in Figure 2.
Actuarial 1-year LC was 91% (34 patients at risk; CI:
82% - 99%) and 2-year LC was 86% (21 patients at risk;
CI: 73% - 98%; Figure 1C). 95% of the lesions treated with
a BED2 > 80Gy were controlled locally after one year. No
local relapses at doses >90 Gy BED2 were observed. Local
progression was observed in only 5 cases, mainly in the
initial dose finding phase, in one patient with an only
retrospectively recognized pleural invasion of the irradi-
ated lesion and in one patient with an extremely large
PTV. Disregarding this case, the variation in PTV was
not extensive (upper limit of tumor diameter: 5 cm) and
no statistically significant influence of PTV size on local
control was found in the range of diameters treated
within this series. Several dose cut off values were tested
statistically. Lesions with a BED2 > 80Gy showed a trend
for better local control (Figure 1D) than lesions treated
with BED2 < 80 Gy. With the limited patient number,
the difference is not statistically significant (p = 0.1167,
Kaplan-Meier log rank). A comparison between NSCLC
and patients with metastases did not show statistically
significant difference in LC.
Most patients died due to systemic metastases with
locally controlled irradiated lesions.
Acute toxicity
7 patients had radiological signs of pneumonitis but no clin-
ical symptoms (grade 1). Clinically apparent pneumonitis(requiring steroid treatment) was present in 23% (n = 9) of
the treated patients. In six patients it was considered grade
2, while three patients developed a respiratory insuffi-
ciency as a consequence of their pneumonitis (grade 3).
Two of them had suffered from severe chronic obstructive
lung disease (COPD) before treatment and one of them
already had a partial respiratory insufficiency. After
conservative treatment of the grade 3 pneumonitis the
functional condition of the patients was restituted to
the pre-SABR state.
Given the fact that prior to SABR 19% (n = 8) of all
patients had severe lung disease (mainly COPD), 36%
(n = 15) had cardiovascular diseases (mainly coronary
heart disease) and 31% (n = 13) suffered from both com-
plicating diagnoses, which cause similar symptoms as ra-
diation pneumonitis, we analyzed the changes in dyspnea
and coughing from pre- to post-SABR with the CTC scale
(Tables 4 and 5). No patient experienced fatal toxicity and
no acute bleedings, fever or lung oedema were observed.
Post-RT aggravation of dyspnea and coughing was ob-
served in 8 of 9 clinically apparent pneumonitis cases.
Grade 1 pleural effusions (with no therapeutic conse-
quence) were observed in 7 cases.Chronic toxicity
Late toxicity was difficult to analyse in this cohort of
patients with advanced tumor stages due to progressive
disease causing symptoms similar to radiation-induced
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fibrosis LENT-SOMA grade 1 was observed in 12 patients
in the follow-up CT, however, patients were clinically in-
apparent. After SABR, 6 patients developed chronic cough
grade 1, with half of them already suffering from chronic
bronchitis and COPD prior to SABR. In the patients alive
at analysis, no change in dyspnea was registered in the
chronic phase, when compared to that in the acute phase.
However, evaluation is difficult (4 patients had died and 2
patients were lost to clinical FU).
Discussion
SABR is a non-invasive therapeutic option for medically
inoperable early stage lung cancer and lung metastases
[21]. Dose escalation [5], which became possible due to
improved planning and delivery techniques, has resulted
in excellent local control rates, as detailed in Table 6: For
stage I NSCLC, at 1 year after therapy, LC of 87-98%
[1,15,21,29,36-43] and for advanced stage NSCLC or
metastases 73-96% are achievable [5,16,22-28]. For pul-
monary metastases, 2- and 3-yr OS rates of 47% and 32%,
and 2- and 3-yr LC rates of 80% (both) with low toxicity
were published recently [30].Table 6 Literature overview SABR, mixed populations (tp = tim
Author year N localisation BED2* (BED10)**
Wulf et al. [22] 51 lung/liver 50 Gy BED2
Hara et al. [23] 59 lung 50-125 Gy BED2
Yoon et al. [24] 101 lung 50-88 Gy BED2
Milano et al. [25] 293
Oligometastases
31-72 Gy BED2
Norihisa et al. [26] 34 oligometastases ~75 Gy BED2
Salazar et al. [27] 109 NSCLC I-IV +
oligometastases
120 Gy BED2
Rusthoven et al. [28] 63 lung 104-150 Gy BED2
McCammon et al. [5] 246 lung/liver 150 Gy BED2
Bradley et al. [12] 91 NSCLC I/II 71-126 Gy BED2
Duncker-Rohr et al. [29] 45 lung (NSCLC
and metastases)
49.5-70.3 Gy BED2
Inoe et al. [30] Lung metastases 106 Gy BED10
(30-168 Gy range)
Inoe et al. [31] 109 NSCLC I 66 Gy BED2
Verstegen et al. [32],
SABR arm
64 NSCLC I-II >100 Gy BED10 9
Kim et al. [33] 16 NSCLC I 88 Gy BED2 96 Gy BED2
Shioyama et al. [34] 8 SCLC stage I 88 Gy BED2
Grills et al. [35] 505 NSCLC I-IIB 132 Gy BED10
*Biologically effective dose in 2Gy fractions (BED2Gy (for α/β 10) was calculated usi
Dx(d+α/β)/(2+α/β).
**BED(for α/β 10)=Dx(1+d/ α/β).Despite our negatively selected patient cohort (high
percentage of metastases of different primaries and 40% >
Stage IIIA primary lung cancers), a 2-yr LC of 85% was
achievable, which is comparable with the results in the
literature in more favourably selected patients. LC in
our cohort was independent of being a primary lung tumor
or a metastasis, while available reports have suggested
better results for (albeit typically earlier stage) primary
lung tumors [44]. Regarding tumor-entities, our cohort was
heterogeneous. This is, however, a situation similarly
encountered in other SABR-series (e.g. [27,45]).
PFS at 2 years of 28% in our cohort is lower than pub-
lished for early stage NSCLC (52-86%, [1,15,21,36-43])
or mixed cohorts (37-81%, [5,16,22-28]). This is probably
due to the extremely negatively selected patients (all stages
included) and high percentage of metastases. Progression
occurred in mediastinal lymph nodes (12%; similar to
literature reports [46]), or distantly (78%). Distant metasta-
ses indicate a clear need for detailed pretreatment staging
(e.g. PET), appropriate selection criteria of patients for
SABR alone and improving systemic therapy [16].
A 2-yr OS of 43% in our cohort is comparable with lit-
erature data (30-78% for NSCLC alone and 30-84% fore point, * = only NSCLC stage I, -: not stated)
OS (tp) PFS (tp) LC (tp)
- - 76% (1 y) 61-76% (2 y)
77% (1 y) 41% (2 y) - 93% (1 y) 78% (2 y)
51% (2 y)* 81% (2 y) 82% (2 y)
- - 77% (2 y) 73% (4 y)
84% (2 y) 35% (2 y) 90% (2 y)
81% (2 y)*
48% (5 y)*
63% 82%
39% (2 y) 37% 100% (1 y) 96% (2 y)
- - 89% (>54 Gy, 3 yr)
58% (3 y) 71% (3 y) 86% (2 y)
52,7% (2 y) - 80,5 (2 y)
47% (2 y) 32% (3 y) 40% (2 y) 32% (3 y) 80% (2 and 3 y)
64% (5 y) 10% (5 y), intrathoracal
progression
78% (5 y)
1.8% (1 y) 79.6% (3 y) 91.6% (1 y) 85.2% (3 y) 96.8% (1 y) 93.3% (3 y)
87.5% (1.5 y) 85.2% (1.5 y) 91% (1.5 y)
72% (3 y) 71% (3 y) 100% (3 y)
60% (2 y) 80% (2 y) 79% (3 y),
distant metastases
94% (2 y)
ng the linear-quadratic model with an assumed α/β ratio of 10: BED2=
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progress (42%), as in most series. This relatively long OS
validates the LC data that might otherwise be biased by
the chance of relapse being reduced by short survival.
This series suggests improved LC with higher doses,
particularly if a BED2 > 80 Gy was applied, though this
difference did not reach statistical significance in this
relatively small cohort. LC after 1 year was maintained
in >95% of the lesions which had been treated with a
BED2 > 90Gy. The reason for the nominally low “thresh-
old” dose for durable local control may be found in the
very high precision in dose delivery using igSABR, thus
reducing the amount of “lost” dose. Similar results were
reported in a recent manuscript by Duncker-Rohr et al.
[29] with 2-yr LC of 95% (NSCLC) and 59,7% (metasta-
ses). Ablation doses might therefore not be as high as
assumed at a time when treatment delivery was less
spatially precise [47].
Toxicity was low despite many comparatively large
lesions in the series. In RTOG-0236, grade 3 and 4 pulmo-
nal side effects were recorded. In our cohort, no worsening
of post-therapeutic symptoms > grade 3 (if compared to
pre-therapeutic symptoms) was recorded. We did not
observe any rib fractures [13,41] or skin toxicity > grade
2. RTOG 0915 will provide further insight as to what
fractionation regimen to use, comparing different fraction-
ation patterns regarding grade 3 toxicities.
Normal lung tolerance forbids, however, the application
of very high doses for centrally located or very large tumors
(>5 cm); which results in more frequent local relapses in
such larger GTVs [21]. The results of RTOG-0813 should
provide us with a recommendation for an effective dose
that can be applied to Stage I central lesions with accept-
able toxicity. Additional dose escalation in the future may
be possible by further PTV-margin reduction through
improvement and clinical integration of immobilization/
tracking methods (breath hold, gating, online tracking
[48]). If currently prohibitive technical limitations in beam
application are overcome and immobilization and imaging
methods known from photon therapy can be imple-
mented successfully, particle therapy might further
improve efficacy [49-53].
Regarding the role of adjuvant chemotherapy in
addition to SABR, CALGB and RTOG are currently
preparing respective trials [54]. In addition, antibodies,
biologicals and radiosensitisers are also under investi-
gation [55,56].Conclusions
Intensity modulated, image-guided breath-hold SABR is an
effective non-invasive treatment modality that enables the
application of reasonably high BED2 which in turn results
in a high local control rate and relatively low toxicity in thisnegatively selected cohort of patients with inoperable lung
tumors and lung metastases. Doses for tumor ablation may
be lower than assumed at a time when delivery techniques
were less precise. As disease progression was mainly
outside the treated area, systemic therapy has to be
further optimized in conjunction with SABR.
Additional file
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